basal insulin plus glp 1 FDA Approves Awiqli® — The First Once-Weekly for Type 2 Diabetes, Novo Nordisk announced that on March 26, 2026, the U.S. FDA approved Awiqli® (insulin icodec-abae) 700 units/mL, the Combination of basal insulin and

de, Weijer, T

Acetyl-L-carnitine as an add-on treatment in fibromyalgia syndrome: a retrospective analysis on 183 patients, according to the generalized linear mixed model for longitudinal data

Women in the same age group who did not have type 2 diabetes had an incidence of 15 per 1,000 women in 2022, compared to zero at baseline

A., Donovan, J

The American Journal of Medicine

CJC-1295 appears to be a synthetic analog made of the first 29 amino acids from the GHRH sequence, which has additional modifications, including the replacement of four amino acids in its structure and the attachment of a Drug Affinity Complex (DAC) to potentially extend the pharmacokinetics of the peptide